Item Details

Print View

The Effect of Federal Ban of RU 486 on Medical Research, New Drug Development, and Pharmaceutical Manufacturers [electronic resource]: Hearing Before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, Second Session, Washington, DC, July 28, 1992

United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Energy
Format
Online; EBook; Government Document
Published
Washington : U.S. G.P.O., 1992.
Language
English
Series
ProQuest U.S. Congressional Hearings Digital Collection
SuDoc Number
Y 4.SM 1:102-85
Description
iii, 144 p. : ill. ; 24 cm.
System requirements: PDF reader software.
Notes
  • Record is based on bibliographic data in ProQuest Congressional Hearings Digital Collection (last viewed Nov. 2009) Reuse except for individual research requires license from ProQuest, LLC.
  • Access to the Congressional Hearings Digital Collection is restricted by license to users on UVA's network. This document may also be available in print or microform at either UVa's Alderman or Law Libraries.
  • CIS No. HRG-1992-SMB-0021
  • Record is based on bibliographic data in ProQuest Congressional Hearings Digital Collection. Reuse except for individual research requires license from ProQuest, LLC.
  • Includes bibliographical references.
Reproduction Notes
Electronic reproduction. [Bethesda, Md.] : ProQuest, 2004. digital, PDF file. ProQuest U.S. Congressional Hearings Digital Collection. Mode of access: World Wide Web via ProQuest website.
Copyright Not EvaluatedCopyright Not Evaluated
Technical Details
  • Staff View

    LEADER 03114nam a22003851a 4500
    001 cis2007462303
    006 m d f
    007 cr bn mmmapmmp
    008 091022s1992 dcua sb f000 0 eng d
    043
      
      
    a| n-us-nj a| n-us---
    074
      
      
    a| 1031-A
    074
      
      
    a| 1031-B (MF)
    086
    0
      
    a| Y 4.SM 1:102-85
    088
      
      
    a| Serial no. 102-85 (United States. Congress. House. Committee on Small Business)
    110
    1
      
    a| United States. b| Congress. b| House. b| Committee on Small Business. b| Subcommittee on Regulation, Business Opportunities, and Energy.
    245
    1
    4
    a| The effect of federal ban of RU 486 on medical research, new drug development, and pharmaceutical manufacturers h| [electronic resource] : b| hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, One Hundred Second Congress, second session, Washington, DC, July 28, 1992.
    260
      
      
    a| Washington : b| U.S. G.P.O., c| 1992.
    300
      
      
    a| iii, 144 p. : b| ill. ; c| 24 cm.
    500
      
      
    a| Record is based on bibliographic data in ProQuest Congressional Hearings Digital Collection (last viewed Nov. 2009) Reuse except for individual research requires license from ProQuest, LLC.
    500
      
      
    a| Access to the Congressional Hearings Digital Collection is restricted by license to users on UVA's network. This document may also be available in print or microform at either UVa's Alderman or Law Libraries.
    500
      
      
    a| CIS No. HRG-1992-SMB-0021
    500
      
      
    a| Record is based on bibliographic data in ProQuest Congressional Hearings Digital Collection. Reuse except for individual research requires license from ProQuest, LLC.
    504
      
      
    a| Includes bibliographical references.
    533
      
      
    a| Electronic reproduction. b| [Bethesda, Md.] : c| ProQuest, d| 2004. e| digital, PDF file. n| ProQuest U.S. Congressional Hearings Digital Collection. n| Mode of access: World Wide Web via ProQuest website.
    538
      
      
    a| System requirements: PDF reader software.
    650
      
    0
    a| Mifepristone x| Government policy z| United States.
    650
      
    0
    a| Medicine x| Research z| United States.
    650
      
    0
    a| Import quotas z| United States.
    650
      
    0
    a| Pharmaceutical policy z| United States.
    776
    0
    8
    i| Print version: a| United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Energy t| Effect of federal ban of RU 486 on medical research, new drug development, and pharmaceutical manufacturers w| (DGPO)93074421 w| (OCoLC)27837766
    776
    0
    8
    i| Microfiche version: a| United States. Congress. House. Committee on Small Business. Subcommittee on Regulation, Business Opportunities, and Energy t| Effect of federal ban of RU 486 on medical research, new drug development, and pharmaceutical manufacturers. d| [Bethesda, Md.] : ProQuest,[2004] o| CIS 93 H721-11 w| (ProQuest)cis09301372
    830
      
    0
    a| ProQuest U.S. Congressional Hearings Digital Collection.
    856
    4
    0
    u| http://proxy.its.virginia.edu/login?url=http://congressional.proquest.com/congcomp/getdoc?HEARING-ID=HRG-1992-SMB-0021 y| Electronic resource (PDF)
    998
      
      
    a| cis09301372
    040
      
      
    a| UMI c| UMI
▾See more
▴See less

Availability

Read Online